Top 5 Most-Read NSCLC Articles of 2025

The top-read articles in non–small cell lung cancer (NSCLC) for The American Journal of Managed Care® covered a variety of topics, including conference coverage of promising phase 2 results, the approval of a new treatment to address EGFR-mutated NSCLC, and reporting on survival outcomes when using cemiplimab in NSCLC.

Here are the top articles in NSCLC in 2025.

5. Cancer-Specific Outcomes Improved With Adherence to Quality Metrics

Patients with early-stage NSCLC were found to have improved outcomes after surgical treatment when they adhered to quality metrics associated with survival. This included oncology referrals, cancer surveillance imaging, and smoking cessation management. Potential disparities were found, however, as those who had lower adherence to quality metrics included those who identified as Black, those who were older, and those with a larger tumor. The participants of the study were all veterans. The reasons for variability in adherence to quality metrics were not evaluated, and only 3 quality metrics were assessed as part of the study, which presented limitations to the study.

Read the full article here.

4. Survival Outcomes in Advanced NSCLC Improved With Use of Cemiplimab

The phase 3 EMPOWER-Lung 3 trial demonstrated that durable and significant improvements in survival outcomes were seen at 5 years of follow-up in patients with NSCLC using cemiplimab plus chemotherapy. These results were presented during the World Conference on Lung Cancer held in Barcelona, Spain, from September 6 to September 9, 2025. The results had previously been published in Nature Medicine, with the 2025 results confirming the initial findings through a median of 60.9 months of follow-up. Median progression-free survival was 8.2 months in those taking cemiplimab compared with 5.5 months in those using chemotherapy alone. Median overall survival was 21.1 months in those taking cemiplimab vs 12.9 months in those taking chemotherapy alone.

Read the full article here.

The top 5 most-read NSCLC articles featured FDA approvals and new trial results presented at conferences | Image credit: Sebastian Kaulitzki - stock.adobe.com

3. FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC

Datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) was approved for use in locally advanced or metastatic EGFR-mutated NSCLC after patients had already received EGFR-directed therapy and platinum-based chemotherapy. The efficacy data from the TROPION-Lung05 and TROPION-Lung01 studies were the basis of the approval, which evaluated 114 patients who had previously received EGFR-directed therapy and platinum-based chemotherapy. The patients were all treated with datopotamab deruxtecan, and the overall response rate was 45%. The median duration of response was 6.5 months. The intravenous infusion is given at 6 mg/kg every 3 weeks up to a maximum of 540 mg for those weighing 90 kg or more.

Read the full article here.

2. Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

The FDA approved telisotuzumab vedotin-tllv (Emrelis; AbbVie) for use in adults with locally advanced or metastatic, non-squamous NSCLC with high c-Met protein overexpression who had previously received a systemic treatment. The approval came as a result of the ongoing phase 2 trial, LUMINOSITY, showing both efficacy and safety in the drug in 84 patients. Overall response rate was 35% in those who used the treatment. The duration of response was an average of 7.2 months. Peripheral edema, fatigue, decreased appetite, and peripheral neuropathy were the most common adverse events in this trial. Telisotuzumab vedotin is also being assessed as a monotherapy in the same population in the TeliMET NSCLC-01 randomized phase 3 global study.

Read the full article here.

1. Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC

Patients with newly diagnosed KRASG123-mutated NSCLC were able to live more than 27 months without disease progression when they used the targeted therapy adagrasib (Krazati; Mirati Therapeutics) combined with the immunotherapy pembrolizumab (Keytruda; Merck). These results were presented at the European Lung Cancer Conference in Paris, France. This treatment was used as a first-line treatment for those with a mutation with PD-L1 of at least 50%. The progression-free survival was 27.7 months, and 60% of the subjects were free of progression through 12 months. Overall survival data were not mature but would continue to be monitored going forward.

Read the full article here.